UNITED THERAPEUTICS CORPORATION

NASDAQ: UTHR (United Therapeutics Corporation)

Last update: 08 Mar, 8:39PM

478.16

-6.90 (-1.42%)

  • 1D -1.42%
  • 5D -10.51%
  • 1M -5.11%
  • 6M 12.69%
  • YTD -3.74%
  • 1Y 55.24%
  • 5Y 182.12%
Previous Close 485.06
Open 478.05
Volume 315,915
Avg. Volume (3M) 405,105
Market Cap 20,956,647,424
Price / Earnings (TTM) 17.16
Price / Earnings (Forward) 19.34
Price / Sales 7.90
Price / Book 3.24
52 Weeks Range
266.98 (-44%) — 537.19 (12%)
Earnings Date 29 Apr 2026
Profit Margin 40.44%
Operating Margin (TTM) 48.19%
Diluted EPS (TTM) 25.11
Quarterly Revenue Growth (YOY) 17.20%
Quarterly Earnings Growth (YOY) 5.10%
Total Debt/Equity (MRQ) 2.94%
Current Ratio (MRQ) 5.46
Operating Cash Flow (TTM) 1.41 B
Levered Free Cash Flow (TTM) 825.79 M
Return on Assets (TTM) 12.93%
Return on Equity (TTM) 19.94%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock United Therapeutics Corporation Bullish Bullish

AIStockmoo Score

1.3
Analyst Consensus 1.5
Insider Activity -3.5
Price Volatility 2.0
Technical Moving Averages 2.5
Technical Oscillators 4.0
Average 1.30

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
UTHR 21 B - 17.16 3.24
NBIX 13 B - 27.77 3.94
HCM 3 B - 5.34 1.92
VTRS 16 B 3.49% - 1.03
BGM 118 M - - 0.660
KNSA 4 B - 61.52 6.21

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Mid Core
% Held by Insiders 1.75%
% Held by Institutions 100.69%
52 Weeks Range
266.98 (-44%) — 537.19 (12%)
Price Target Range
466.00 (-2%) — 705.00 (47%)
High 705.00 (UBS, 47.44%) Buy
Median 600.00 (25.48%)
Low 466.00 (Wells Fargo, -2.54%) Hold
Average 602.00 (25.90%)
Total 6 Buy, 1 Hold
Avg. Price @ Call 505.13
Firm Date Target Price Call Price @ Call
Cantor Fitzgerald 12 Mar 2026 625.00 (30.71%) Buy 532.82
UBS 05 Mar 2026 705.00 (47.44%) Buy 485.06
06 Jan 2026 645.00 (34.89%) Buy 502.71
HC Wainwright & Co. 26 Feb 2026 600.00 (25.48%) Buy 503.60
Oppenheimer 26 Feb 2026 600.00 (25.48%) Buy 503.60
RBC Capital 26 Feb 2026 643.00 (34.47%) Buy 503.60
TD Cowen 26 Feb 2026 575.00 (20.25%) Buy 503.60
Wells Fargo 26 Feb 2026 466.00 (-2.54%) Hold 503.60
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BENKOWITZ MICHAEL - 536.12 -14,706 -7,884,181
EDGEMOND JAMES - 536.12 -8,786 -4,710,350
MAHON PAUL A - 531.56 -16,663 -8,857,672
MALCOLM JAN - 540.02 -45 -24,301
OLIAN JUDY D. - 534.30 -200 -106,860
ROTHBLATT MARTINE A - 534.03 -77,212 -41,272,263
Aggregate Net Quantity -117,612
Aggregate Net Value ($) -62,855,627
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 534.45
Name Holder Date Type Quantity Price Value ($)
MAHON PAUL A Officer 19 Mar 2026 Automatic sell (-) 8,300 527.00 4,374,100
MAHON PAUL A Officer 19 Mar 2026 Option execute 8,300 - -
ROTHBLATT MARTINE A Officer 19 Mar 2026 Automatic sell (-) 9,500 527.00 5,006,500
ROTHBLATT MARTINE A Officer 19 Mar 2026 Option execute 9,500 - -
ROTHBLATT MARTINE A Officer 18 Mar 2026 Automatic sell (-) 9,500 530.35 5,038,325
ROTHBLATT MARTINE A Officer 18 Mar 2026 Option execute 9,500 - -
MALCOLM JAN Director 17 Mar 2026 Automatic sell (-) 45 540.02 24,301
ROTHBLATT MARTINE A Officer 17 Mar 2026 Automatic sell (-) 9,500 540.02 5,130,190
ROTHBLATT MARTINE A Officer 17 Mar 2026 Option execute 9,500 - -
OLIAN JUDY D. Director 16 Mar 2026 Automatic sell (-) 200 534.30 106,860
ROTHBLATT MARTINE A Officer 16 Mar 2026 Automatic sell (-) 516 534.30 275,699
ROTHBLATT MARTINE A Officer 16 Mar 2026 Automatic sell (-) 9,500 534.30 5,075,850
ROTHBLATT MARTINE A Officer 16 Mar 2026 Option execute 9,500 - -
ROTHBLATT MARTINE A Officer 15 Mar 2026 Disposed (-) 29,196 536.12 15,652,560
ROTHBLATT MARTINE A Officer 15 Mar 2026 Option execute 69,579 - -
MAHON PAUL A Officer 15 Mar 2026 Disposed (-) 8,363 536.12 4,483,572
MAHON PAUL A Officer 15 Mar 2026 Option execute 16,691 - -
EDGEMOND JAMES Officer 15 Mar 2026 Disposed (-) 8,786 536.12 4,710,350
EDGEMOND JAMES Officer 15 Mar 2026 Option execute 19,478 - -
BENKOWITZ MICHAEL Officer 15 Mar 2026 Disposed (-) 14,706 536.12 7,884,181
BENKOWITZ MICHAEL Officer 15 Mar 2026 Option execute 33,382 - -
ROTHBLATT MARTINE A Officer 13 Mar 2026 Automatic sell (-) 9,500 536.12 5,093,140
ROTHBLATT MARTINE A Officer 13 Mar 2026 Option execute 9,500 - -
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria